Exon 45 skipping and dystrophin production with ENTR-601-45 in preclinical models of Duchenne muscular dystrophy

被引：0

作者：

Girgenrath, M. ^{[1
]}

Estrella, N. ^{[1
]}

Kumar, A. ^{[1
]}

Hicks, A. ^{[1
]}

Brennan, C. ^{[1
]}

Blake, S. ^{[1
]}

Li, X. ^{[1
]}

Pathak, A. ^{[1
]}

Kheirabadi, M. ^{[1
]}

Dougherty, P. ^{[1
]}

Lian, W. ^{[1
]}

Liu, N. ^{[1
]}

Gao, N. ^{[1
]}

Wang, D. ^{[1
]}

Streeter, M. ^{[1
]}

Stadheim, A. ^{[1
]}

Dhanabal, M. ^{[1
]}

Qian, Z. ^{[1
]}

机构：

[1] Entrada Therapeut, Boston, MA USA

来源：

NEUROMUSCULAR DISORDERS | 2024年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

431P

引用

页数：2

共 50 条

[41] Exon skipping: a first in class strategy for Duchenne muscular dystrophy
Niks, Erik H.
Aartsma-Rus, Annemieke
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (02) : 225 - 236
[42] The Status of Exon Skipping as a Therapeutic Approach to Duchenne Muscular Dystrophy
Lu, Qi-Long
Yokota, Toshifumi
Takeda, Shin'ichi
Garcia, Luis
Muntoni, Francesco
Partridge, Terence
MOLECULAR THERAPY, 2011, 19 (01) : 9 - 15
[43] Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy
Aartsma-Rus, Annemieke
Heemskerk, Hans
de Winter, Christa
van Putten, Maaike
Janson, Anneke
Verschuuren, Jan
den Dunnen, Johan
van Deutekom, Judith
van Ommen, Gert-Jan
HUMAN GENE THERAPY, 2009, 20 (06) : 660 - 661
[44] Skipping along: an exon skipping therapy shows promise for Duchenne muscular dystrophy
Hawkins, A. K.
CLINICAL GENETICS, 2011, 80 (05) : 424 - U27
[45] Optimization of antisense-mediated exon skipping in mouse models for Duchenne muscular dystrophy
Aartsma-Rus, A.
Heemskerk, H. A.
de Winter, C. L.
van Putten, M.
De Kimpe, S.
van Deutekom, J. C. T.
van Ommen, G. J. B.
NEUROMUSCULAR DISORDERS, 2008, 18 (9-10) : 757 - 757
[46] Systemic Antisense-Mediated Exon Skipping in Mouse Models for Duchenne Muscular Dystrophy
Aartsma-Rus, Annemieke
Heemskerk, Hans
De Winter, Christa
Van Putten, Maaike
Janson, Anneke
Verschuuren, Jan
Den Dunnen, Johan
Van Deutekom, Judith
Van Ommen, Gert-Jan
MOLECULAR THERAPY, 2009, 17 : S166 - S166
[47] Restoration of full-length dystrophin expression through exon skipping in Duchenne muscular dystrophy patients with single exon duplications
Nicolau, S.
Malhotra, J.
Iammarino, M.
Reash, N.
Lowes, L.
Flanigan, K.
NEUROMUSCULAR DISORDERS, 2022, 32
[48] Three-dimensional gait analysis of Duchenne muscular dystrophy: A trial to evaluate the therapeutic effect of RNA/ENA chimera antisense oligonucleotide that induces dystrophin exon 45 skipping
Takeshima, Y.
Yagi, M.
Lee, T.
Kusunoki, N.
Ojima, I.
Minami, S.
Asai, T.
Nakagawa, A.
Iijima, K.
Matsuo, M.
NEUROMUSCULAR DISORDERS, 2013, 23 (9-10) : 803 - 803
[49] Development of an orally available inhibitor of CLK1 for skipping a mutated dystrophin exon in Duchenne muscular dystrophy
Sako, Yukiya
Ninomiya, Kensuke
Okuno, Yukiko
Toyomoto, Masayasu
Nishida, Atsushi
Koike, Yuka
Ohe, Kenji
Kii, Isao
Yoshida, Suguru
Hashimoto, Naohiro
Hosoya, Takamitsu
Matsuo, Masafumi
Hagiwara, Masatoshi
SCIENTIFIC REPORTS, 2017, 7
[50] Exon skipping and dystrophin restoration in Duchenne muscular dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment
Cirak, S.
Arechavala-Gomeza, V.
Guglieri, M.
Feng, L.
Torelli, S.
Anthony, K.
Garralda, M. E.
Wells, D.
Dickson, G.
Wood, M. J. A.
Wilton, S. D.
Straub, V.
Shrewsbury, S. B.
Sewry, C.
Morgan, J. E.
Bushby, K.
Muntoni, F.
NEUROMUSCULAR DISORDERS, 2011, 21 : S7 - S8

← 1 2 3 4 5 →